𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia

✍ Scribed by Dr G. Chikkappa; A. L. Carsten; A. D. Chanana; P. Chandra; E. P. Cronkite

Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
554 KB
Volume
4
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Dysregulation and overexpression of HMGA
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia
✍ Joris Andrieux; Jean-Loup Demory; Brigitte Dupriez; Sabine Quief; Isabelle Plant πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 262 KB

Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32

Prognostic diversity among cytogenetic a
Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
✍ Ayalew Tefferi; David Dingli; Chin-Yang Li; Gordon W. Dewald πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## Abstract ## BACKGROUND Approximately 30–50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely defined by previous retrospective studies. The current prospective study addresses thi

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a